IBRX ImmunityBio Inc

Price (delayed)

$3.69

Market cap

$1.47B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.94

Enterprise value

$2.08B

NantKwest (NASDAQ: NK) is an innovative, clinical-stage, immunotherapy company focused on harnessing the power of the innate immune system to treat cancer and infectious diseases. NantKwest is the leading producer ...

Highlights
ImmunityBio's revenue has increased by 40% YoY but it has decreased by 13% QoQ
The company's gross profit rose by 40% YoY but it fell by 13% QoQ
The debt has surged by 103% year-on-year
ImmunityBio's equity has shrunk by 81% YoY and by 39% QoQ

Key stats

What are the main financial stats of IBRX
Market
Shares outstanding
397.96M
Market cap
$1.47B
Enterprise value
$2.08B
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
N/A
Price to sales (P/S)
1,814.82
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
2,572.16
Earnings
Revenue
$809,000
EBIT
-$349.83M
EBITDA
-$329.82M
Free cash flow
-$322.21M
Per share
EPS
-$0.94
Free cash flow per share
-$0.81
Book value per share
-$0.84
Revenue per share
$0
TBVPS
$0.92
Balance sheet
Total assets
$389.59M
Total liabilities
$727.14M
Debt
$648.8M
Equity
-$335.64M
Working capital
-$168.67M
Liquidity
Debt to equity
-1.93
Current ratio
0.56
Quick ratio
0.52
Net debt/EBITDA
-1.86
Margins
EBITDA margin
-40,769.3%
Gross margin
100%
Net margin
-45,735.7%
Operating margin
-42,025.7%
Efficiency
Return on assets
-112.2%
Return on equity
N/A
Return on invested capital
-69.8%
Return on capital employed
-4,080.6%
Return on sales
-43,241.9%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

IBRX stock price

How has the ImmunityBio stock price performed over time
Intraday
-1.07%
1 week
3.07%
1 month
-5.87%
1 year
-74.62%
YTD
-39.31%
QTD
-34.22%

Financial performance

How have ImmunityBio's revenue and profit performed over time
Revenue
$809,000
Gross profit
$809,000
Operating income
-$339.99M
Net income
-$370M
Gross margin
100%
Net margin
-45,735.7%
ImmunityBio's revenue has increased by 40% YoY but it has decreased by 13% QoQ
ImmunityBio's net income has decreased by 40% YoY and by 7% QoQ
The company's gross profit rose by 40% YoY but it fell by 13% QoQ
IBRX's operating income is down by 26% year-on-year and by 2.9% since the previous quarter

Growth

What is ImmunityBio's growth rate over time

Valuation

What is ImmunityBio stock price valuation
P/E
N/A
P/B
N/A
P/S
1,814.82
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
2,572.16
ImmunityBio's EPS has decreased by 34% YoY and by 6% QoQ
ImmunityBio's equity has shrunk by 81% YoY and by 39% QoQ
The P/S is 72% less than the last 4 quarters average of 6576.9 and 68% less than the 5-year quarterly average of 5726.0
ImmunityBio's revenue has increased by 40% YoY but it has decreased by 13% QoQ

Efficiency

How efficient is ImmunityBio business performance
The company's return on invested capital rose by 30% YoY and by 4.9% QoQ
ImmunityBio's return on sales has decreased by 22% QoQ but it has increased by 2.2% YoY
IBRX's return on assets is up by 14% year-on-year and by 8% since the previous quarter

Dividends

What is IBRX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for IBRX.

Financial health

How did ImmunityBio financials performed over time
The total assets is 46% less than the total liabilities
The total assets has soared by 86% YoY but it has contracted by 17% from the previous quarter
ImmunityBio's total liabilities has soared by 84% YoY and by 2% from the previous quarter
The debt has surged by 103% year-on-year
ImmunityBio's equity has shrunk by 81% YoY and by 39% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.